remikiren
Sign in to saveRemikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.
Research
68 papers- Discovery of remikiren as the first orally active renin inhibitor.Arzneimittel-Forschung · 1993
- Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system.American journal of hypertension · 1996
- Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals.Xenobiotica; the fate of foreign compounds in biological systems · 1996
- Interaction of the renin inhibitor aliskiren with the SARS-CoV-2 main protease: a molecular docking study.Journal of biomolecular structure & dynamics · 2022
- Excretion and metabolism of remikiren, a potent orally active inhibitor of primate renin.Xenobiotica; the fate of foreign compounds in biological systems · 1996
via PubMed
Wikidata facts
- Mass
- 630.345
Show 4 more facts
- chemical formula
- C₃₃H₅₀N₄O₆S
- World Health Organisation international non-proprietary name
- remikiren
- isomeric SMILES
- CC(C)(C)S(=O)(=O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3CCCCC3)[C@H]([C@H](C4CC4)O)O
- canonical SMILES
- CC(C)(C)S(=O)(=O)CC(CC1=CC=CC=C1)C(=O)NC(CC2=CN=CN2)C(=O)NC(CC3CCCCC3)C(C(C4CC4)O)O
Sources (2)
via Wikidata · CC0
~1 min read
Article
1 sectionsContents
- References
Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.
==References==
Connections
angiotensins
Entity
amlodipine/valsartan
Entity
perindopril
Entity
irbesartan
Entity
medication
Entity
circulatory system
Entity
arterial hypertension
Entity
digital object identifier
Entity
chemical formula
Entity
molar mass
Entity
Q180686
Entity
CAS Registry Number
Entity
PubChem
Entity
Anatomical Therapeutic Chemical Classification System
Entity
World Health Organization Model List of Essential Medicines
Entity
clinical trial
Entity
simplified molecular input line entry specification
Entity
renin–angiotensin system
Entity
Hoffmann-La Roche
Company
ACE inhibitor
Entity